Wed, Apr 16, 2014, 1:02 PM EDT - U.S. Markets close in 2 hrs 58 mins

Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • michael_d_angelo michael_d_angelo Feb 14, 2013 2:22 PM Flag

    Stifel, Baird and Piper Jaffray maintain their equivalent of a Buy rating on shares of Affymax.

    Affymax Shares Fall Amid Plan to Halt Expansion of Pilot, Pare Loss as Analysts Defend
    1:29p ET February 14, 2013 (Benzinga)
    Shares of Affymax (NASDAQ: AFFY) gapped more than 30 percent lower at Thursday morning's open following an 8-K which disclosed the company will halt the expansion of its Omontys pilot. The company suggested continuing use of Omontys for the management of anemia.

    The stock began bouncing shortly after the open as traders began passing around research notes which suggested the news is not as bad as feared.

    Affymax shares are now down around 6 percent heading into the last few hours of trade. The stock last traded around $15.60.

    In addition to being defended at Stifel Nicolaus and Baird, a Piper Jaffray analyst argued Affymax shares could move into the mid-$20 range by the end of April if a deal for Omontys with Fresenius Medical is agreed upon. Related to the concern of allergic reactions, the Piper analyst noted these reactions were "very small" and should not be concerning to doctors. The analyst believes many doctors prefer Omontys and said "they want to keep their patients on it."

    Stifel, Baird and Piper Jaffray maintain their equivalent of a Buy rating on shares of Affymax.

    Sentiment: Strong Buy

 
AFFY
0.65+0.01(+1.72%)12:46 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.